- Home
- GHLD vs ELVN Comparison
GHLD vs ELVN Comparison
Compare GHLD & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHLD
- ELVN
- Stock Information
- Founded
- GHLD 1960
- ELVN 2016
- Country
- GHLD United States
- ELVN United States
- Employees
- GHLD N/A
- ELVN N/A
- Industry
- GHLD Finance: Consumer Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- GHLD Finance
- ELVN Health Care
- Exchange
- GHLD Nasdaq
- ELVN Nasdaq
- Market Cap
- GHLD 813.7M
- ELVN 927.8M
- IPO Year
- GHLD 2020
- ELVN 2020
- Fundamental
- Price
- GHLD $19.76
- ELVN $21.30
- Analyst Decision
- GHLD Hold
- ELVN Strong Buy
- Analyst Count
- GHLD 6
- ELVN 5
- Target Price
- GHLD $16.30
- ELVN $39.60
- AVG Volume (30 Days)
- GHLD 67.2K
- ELVN 594.3K
- Earning Date
- GHLD 08-07-2025
- ELVN 08-12-2025
- Dividend Yield
- GHLD 2.53%
- ELVN N/A
- EPS Growth
- GHLD 63.18
- ELVN N/A
- EPS
- GHLD 0.71
- ELVN N/A
- Revenue
- GHLD $1,131,796,000.00
- ELVN N/A
- Revenue This Year
- GHLD $5.64
- ELVN N/A
- Revenue Next Year
- GHLD $26.37
- ELVN N/A
- P/E Ratio
- GHLD $27.80
- ELVN N/A
- Revenue Growth
- GHLD 32.57
- ELVN N/A
- 52 Week Low
- GHLD $11.21
- ELVN $13.30
- 52 Week High
- GHLD $20.15
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- GHLD 82.47
- ELVN 55.53
- Support Level
- GHLD $14.69
- ELVN $18.53
- Resistance Level
- GHLD $20.15
- ELVN $24.11
- Average True Range (ATR)
- GHLD 0.63
- ELVN 1.96
- MACD
- GHLD 0.54
- ELVN 0.15
- Stochastic Oscillator
- GHLD 94.54
- ELVN 55.68
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.